Literature DB >> 31303409

Predictors of Systolic Heart Failure and Mortality Following Orthotopic Liver Transplantation: a Single-Center Cohort.

Antoine E Sakr1, Gary E Fraser2, Tanya P Doctorian2, Hyungjin B Kim2, Deepika Narasimha2, Islam Abudayyeh2, Anthony D Hilliard2, Wendy Shih3, Michael E de Vera4, Pedro W Baron4, Michael L Volk4, Liset N Stoletniy2.   

Abstract

OBJECTIVES: The purpose of this study was to identify risk factors that may predict heart failure with reduced ejection fraction (HFrEF) following orthotopic liver transplantation (OLT) and associated mortality.
BACKGROUND: HFrEF following OLT is a poorly understood phenomenon, reported in 3% to 7% of transplanted patients.
METHODS: This is a retrospective analysis of 176 consecutive patients who underwent OLT from 2010 to 2017. Multivariate logistic regression was used to identify associations between cardiovascular risk factors and perioperative variables with post-OLT HFrEF, defined as reduction in left ventricular ejection fraction of at least 10% and left ventricular ejection fraction less than or equal to 40% with acute heart failure symptoms. Multivariate cox proportional hazards regression (with inverse probability weighting by propensity scores) was used to evaluate effects of HFrEF on 1-year mortality.
RESULTS: Of the176 patients, 14% developed HFrEF with a median of 5 days. History of heart failure (OR 10.99, 2.15-56.09; P = .04) and intraoperative transfusion of greater than 11 units of packed red blood cells (OR 3.377, 1.025-11.13; P = .045) were associated with increased incidence of HFrEF. Pre-transplant hemoglobin greater than 8.5 g/dL (OR 0.252, CI 0.0954- 0.665; P = .05) was protective against HFrEF. Thirty-three percent of HFrEF group died within 1 year (HR 7.36, 2.57-21.12; P < .001).
CONCLUSIONS: The incidence of acute HFrEF post-OLT is 14% and is associated with a 7-fold increase in 1-year mortality. Cirrhotic cardiomyopathy and stress-induced cardiomyopathy maybe the underlying mechanisms. Our study identified risk factors associated with post-OLT HFrEF and should provide additional guidance for risk stratification of patients undergoing OLT.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31303409     DOI: 10.1016/j.transproceed.2019.04.063

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  2 in total

Review 1.  Management of cardiac diseases in liver transplant recipients: Comprehensive review and multidisciplinary practice-based recommendations.

Authors:  Manhal Izzy; Brett E Fortune; Marina Serper; Nicole Bhave; Andrew deLemos; Juan F Gallegos-Orozco; Cesar Guerrero-Miranda; Shelley Hall; Matthew E Harinstein; Maria G Karas; Michael Kriss; Nicholas Lim; Maryse Palardy; Deirdre Sawinski; Emily Schonfeld; Anil Seetharam; Pratima Sharma; Jose Tallaj; Darshana M Dadhania; Lisa B VanWagner
Journal:  Am J Transplant       Date:  2022-03-31       Impact factor: 9.369

2.  Prevalence and prognostic value of cirrhotic cardiomyopathy as defined according to the proposed new classification.

Authors:  Maurizio Cesari; Anna Chiara Frigo; Salvatore Piano; Paolo Angeli
Journal:  Clin Exp Hepatol       Date:  2021-08-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.